Cedara I-Response from Merge Healthcare

Merge Healthcare (Booth 4058) is demonstrating the capabilities of its Cedara I-Response, an application designed to support clinical trial workflow and oncology viewing.

Cedara I-Response supports key concepts of double-blind reading, registration, advanced segmentation, comparison of multiple time points and support for clinical trial rules and has three distinct analysis techniques.  

The base Lesion Analysis package streamlines the clinical trials workflow of creating/exporting the RECIST, WHO and Volume measurements.  The PET/CT Analysis package enables users to compare standardized uptake values (SUV) over multiple time points.  The Functional Diffusion Mapping (fDM) Analysis package can track changes in tumors at the metabolic or cellular level over multiple time points. The fDM tool is a patented MR tumor analysis technique.